Table 1.
Dosing and timing recommendations for HPV vaccine administration.
| Age | Healthy Individuals | KT Recipients* |
|---|---|---|
| 9 to 15 | Two doses of HPV vaccine at month: | Three doses of HPV vaccine at month: |
| −0 | −0 | |
| −6–12 | −1–2 | |
| −6 | ||
| 15 to 26 | Three doses of HPV vaccine at month: | Three doses of HPV vaccine at month: |
| −0 | −0 | |
| −1–2 | −1–2 | |
| −6 | −6 | |
| 26–45 | Not routinely offered | Should be considered** |
For HPV vaccine administration in KT recipients it is recommended to wait 3–6 months after transplant, similar to other non-live vaccines except influenza.
HPV vaccination is safe for adults aged 26 through 45 years, however population benefit is minimal; however, KT recipients who are not adequately vaccinated may be at risk for new HPV infection and therefore might benefit from vaccination in this age range. Therefore, should be considered in individual cases as shared clinical decision-making between patient and provider.